Axsome Therapeutics, Inc. $AXSM Shares Newly Bought by New York Life Investment Management LLC

New York Life Investment Management LLC acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 5,903 shares of the company’s stock, valued at approximately $1,088,000.

Other large investors also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Axsome Therapeutics in the 2nd quarter valued at about $759,695,000. First Trust Advisors LP boosted its holdings in shares of Axsome Therapeutics by 1,230.2% during the 1st quarter. First Trust Advisors LP now owns 577,479 shares of the company’s stock worth $97,606,000 after purchasing an additional 534,066 shares during the last quarter. Bank of America Corp DE acquired a new position in shares of Axsome Therapeutics during the 2nd quarter worth approximately $110,756,000. Canada Pension Plan Investment Board acquired a new position in shares of Axsome Therapeutics during the 2nd quarter worth approximately $55,171,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Axsome Therapeutics in the second quarter valued at approximately $48,275,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Price Performance

AXSM stock opened at $141.69 on Monday. The firm has a market cap of $7.45 billion, a PE ratio of -46.30 and a beta of 0.86. The company has a debt-to-equity ratio of 1.21, a quick ratio of 1.34 and a current ratio of 1.42. The firm’s 50 day moving average price is $171.45 and its 200-day moving average price is $196.75. Axsome Therapeutics, Inc. has a one year low of $123.00 and a one year high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.38. The firm had revenue of $259.69 million for the quarter, compared to analysts’ expectations of $249.19 million. Axsome Therapeutics had a negative return on equity of 198.73% and a negative net margin of 18.18%. The firm’s quarterly revenue was up 51.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.94) earnings per share. On average, equities research analysts anticipate that Axsome Therapeutics, Inc. will post -2.27 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AXSM. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Thursday, October 15th. Truist Financial lifted their price objective on Axsome Therapeutics from $200.00 to $285.00 and gave the stock a “buy” rating in a research report on Wednesday, September 23rd. Robert W. Baird lowered their price objective on Axsome Therapeutics from $246.00 to $220.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 3rd. UBS Group dropped their target price on Axsome Therapeutics from $256.00 to $239.00 and set a “buy” rating for the company in a report on Tuesday, November 3rd. Finally, Deutsche Bank cut their target price on Axsome Therapeutics from $280.00 to $267.00 and set a “buy” rating for the company in a research note on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Axsome Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $266.21.

Read Our Latest Stock Report on AXSM

Insider Buying and Selling

In other Axsome Therapeutics news, COO Mark Jacobson sold 10,000 shares of Axsome Therapeutics stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total value of $2,086,500.00. Following the sale, the chief operating officer owned 10,000 shares in the company, valued at $2,086,500. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 20.60% of the stock is owned by corporate insiders.

Axsome Therapeutics Company Profile

(Free Report)

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

Read More

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.